Table S2 Characteristics of included studies First Author Year Country Median follow-up (months) Sample size Mean age (years) Male:Female (count) Anatomical location of aneurysms Device Case series 1 Semmens 2006 Australia (Multicentre) 16.8* 58 75.5 51:7 AAA Zenith fenestrated device (Cook Ltd, Brisbane, Australia) 2 O’Neill 2006 US (Cleveland) 19* 119 75 98:21 Juxtarenal AAA Zenith fenestrated device (Cook Inc, Bloomington, Ind) 3 Ziegler 2007 Germany (Frankfurt) 14 63 70.5 57:6 Para-anastomotic, thoracoabdominal, thoracic AAA Zenith fenestrated device (Cook Ltd, Brisbane, Australia) 4 Greenberg 2009 US (Multicentre) 24 30 75 24:6 Juxtarenal AAA Zenith fenestrated device (Cook Inc, Bloomington, Ind) 5 Verhoeven 2010 Netherlands (Groningen) 24 100 72.6 87:13 Short-necked or juxtarenal AAA Zenith fenestrated device (Cook Inc, Bloomington, Ind) 6 Amiot 2010 France (Multicentre) 15 134 73¶ 129:5 Juxtarenal, suprarenal or type IV thoraco-AAA Zenith fenestrated device (Cook Inc, Bloomington, Ind) 7 Tambyraja 2011 UK (Leicester) 20 29 74¶ 27:2 Juxtarenal AAA Zenith fenestrated device (Cook Inc, Bloomington, Ind) 8 2013 Chile France New Zealand UK US 15.6* 31 73 28:3 Juxtarenal and pararenal AAA Ventana fenestrated stent graft (EndologixInc, Irvine, Calif)
16 Moore 2006 Canada Min 1 16 77 15:1 Juxtarenal AAA Zenith fenestrated device (Cook Inc, Bloomington, Ind) 17 Chisci 2009 Italy Sweden 13.9* 52 71.5 42:10 Superior mesenteric artery, renal arteries, all visceral vessels with asymptomatic AAA with challenging proximal neck Zenith fenestrated device (Cook Ltd, Brisbane, Australia) 18 Donas 2012 Germany (Munster) 13.2* 29 73.7 29:0 Juxtarenal AAA Zenith fenestrated device (Cook Inc, Bloomington, Ind) 19 GLOBALSTAR 2012 UK (Multicentre) 6 318 74 273:45 Juxtarenal and pararenal AAA Zenith fenestrated device (Cook Inc, Bloomington, Ind) 20 Canavati 2013 UK (Liverpool) NR 53 72¶ 47:6 Juxtarenal AAA Zenith fenestrated device (Cook Inc, Bloomington, Ind) 21 Tsilimparis 2013 US (Multicentre) Min 1 OSR = 1091 fEVAR = 264 OSR = 71 fEVAR = 74 OSR = 780:311 fEVAR= 217:47 cAAA Customized and surgeon-modified stent grafts 22 Raux 2014 US France Min 1 ‡OSR = 147 fEVAR = 42 OSR = 73 fEVAR = 73 OSR = 120:27 fEVAR = 37:5 cAAA Zenith fenestrated device (Cook Ltd, Brisbane, Australia) * Mean follow-up § Median age ‡ Propensity-matched dataset
6. Did participants enter the study at a similar point in the disease? 7. Was the clearly described in the study? 8. Were additional interventions (co-interventions) clearly reported in the study? 9. Are the outcome measures clearly defined in the introduction or methods section? (30-day mortality) 10. Were relevant outcomes appropriately measured with objective and/or subjective methods? (30-day mortality) 11. Were outcomes measured before and after intervention? (30-day mortality) 12. Were the statistical tests used to assess the relevant outcomes appropriate? 13. Was the length of follow-up reported? 14. Was the loss to follow-up reported? 15. Does the study provide estimates of the random variability in the data analysis of relevant outcomes? 16. Are adverse events reported? (30-day follow-up) 17. Are the conclusions of the study supported by results? 18. Are both competing interest and source of support for the study reported? 19. Have the authors taken account of potential confounding factors in the design or analyses? 20. Are results adjusted for confounding? 21. Has adjustment made a big difference? Table S4 Thirty-day mortality or peri-operative mortality in comparative studies Unadjusted Unadjusted Unadjusted Adjusted Adjusted Method of adjustment Endpoint in